Engrail Therapeutics closes oversubscribed $157 million Series B financing
Vikram Sudarsan, Ph.D., president and CEO of Engrail Therapeutics Engrail Therapeutics, a precision neuroscience company, announced the closure of
Continue reading
Tag: neuroscience company